Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?

Halozyme Therapeutics (HALO) shares have declined 23.2% in the past month, underperforming the S&P 500, despite upward revisions to estimates. The stock has a Zacks Rank #2 (Buy), and the company is expected to have above-average returns in the next few months. In comparison, Incyte (INCY), another stock in the same industry, has gained 13.2% over the past month, with a 19.5% increase in revenue and EPS of $1.16, compared to $0.64 a year ago.

Analysis

Halozyme Therapeutics (HALO) shares have declined significantly by 23.2% in the month following its last earnings report, markedly underperforming the S&P 500. This decrease occurred despite fresh earnings estimates trending upwards over the past two months. Fundamentally, Halozyme Therapeutics exhibits strength, evidenced by a 'Great' Growth Score of A and a Value Score of A, contributing to an aggregate VGM Score of A, although its Momentum Score is a B. Zacks has assigned HALO a Rank #2 (Buy), indicating an expectation of above-average stock returns in the near term. In contrast, Incyte (INCY), a peer in the Zacks Medical - Biomedical and Genetics industry, has experienced a 13.2% gain in its share price over the past month. Incyte reported strong results for the quarter ended March 2025, with revenues of $1.05 billion, a 19.5% year-over-year increase, and an EPS of $1.16, up from $0.64 in the comparable prior-year period. Incyte is projected to report earnings of $1.38 per share for the current quarter, representing a substantial year-over-year change of +175.8%; however, its Zacks Consensus Estimate has decreased by 0.6% over the last 30 days, leading to a Zacks Rank #3 (Hold), despite also having a VGM Score of A.

Key Decisions for Investors

• Investors should evaluate whether the recent 23.2% share price decline in Halozyme Therapeutics (HALO) presents a buying opportunity, considering its strong VGM scores, upward estimate revisions, and Zacks #2 (Buy) rating.
• Monitor upcoming catalysts for HALO, particularly its next earnings release, to determine if the negative stock performance will align with or diverge further from its positive fundamental outlook and analyst expectations.
• For Incyte (INCY), while past performance and near-term earnings growth projections are strong, the Zacks #3 (Hold) rating and recent slight downward estimate revision suggest a cautious approach, potentially holding existing positions rather than initiating new ones pending further confirmation of sustained momentum.